In in vivo experiments, using a xenograft mouse model of human MLS, a marked reduction of human CCL2, CXCL8 and PTX3 after trabectedin administration was observed, demonstrating that this effect on tumor cells occurs also in vivo (39). The gene discussed is CCL2; the disease is neoplasm.